Lysosome biology studies the structure, physiological properties and cellular functions of lysosomes. It involves the study of lysosomes, interactions between cells and their surroundings, life cycle, differentiation and death. Among them, autophagy is a process that engulfs its own cytoplasmic proteins or organelles and encapsulates them into vesicles, which fuse with lysosomes to form autophagic lysosomes that degrade their encapsulated contents. In mammalian cells, there are three main types of autophagy: microautophagy, macroautophagy, and molecular chaperone-mediated autophagy (CMA). Therefore, the development of effective inhibitors and agonists of lysosomal autophagy is crucial to analyze the pathogenesis of lysosome-related tumors, neurodegenerative diseases, metabolism-related diseases, and immune disorders.
For researchers in the field of lysosome biology, inhibitors and activators are critical research tools in order to more fully understand lysosomal function, cellular signaling, and the intracellular mechanisms that control cell fate, function, and phenotype. In addition, cellular autophagic activity at the cellular basal level is very low and unsuitable for observation; therefore, most studies of cellular autophagy require manual intervention. Working closely with experts in other biological fields such as genetics, molecular biology, developmental biology and biochemistry, our team of experts is dedicated to the development of lysosomal agonists and inhibitors for lysosomal biology and autophagy research.
CD BioSciences is your partner for lysosomal agonists and inhibitors from concept to commercialization. Our small molecule products consist of agonists, partial agonists, activators, inhibitors, positive-metamorphic modulators (PAMs) and negative-metamorphic modulators (NAMs) and are classified according to drug target and pharmacological action. Markets served include research and laboratory. Our lysosomal agonists and inhibitors in development include, but are not limited to：
- Analysis of lysosomal kinetics and function.
- Assessment lysosomal tissue protease activity.
- To study lysosomal endo-hydrolysis, lysosomal membrane permeability.
- For T cell-mediated inflammation studies.
- To study autophagic processes.
- To study neurodegenerative diseases, metabolism-related diseases, and immune diseases associated with lysosomal dysfunction.
- Our lab has high-throughput, image-based screens for isolating small molecule regulators of lysosomes.
- Allows for quantitative analysis of autophagic vesicles in fluorescent images.
- Allows identification of lysosomal small molecule regulators with certain specificities
- Provides multiple target designs for autophagy regulators.
- Provides potential lead candidates for the development of new therapies for human diseases.
❖ mTOR signal transduction inhibitors.
❖ AMPK activators.
❖ VPS34 kinase complex inhibitors.
❖ PI3K signal transduction inhibitors.
❖ Ca2+ channel antagonists.
❖ Inositol monophosphatase inhibitors .
❖ Lysosomal alkalinizing agents.
❖ Lysosomal acidifiers.
❖ Vesicular H+-ATPase inhibitors.
❖ ATPase inhibitors.
Of note: While we are still in the early stages of developing lysosomal pharmacological modulators, the identification of small molecule modulators may provide important insights into the mechanisms that regulate lysosomes.
Applications of Lysosomal Inhibitors & Agonists
Why Choose Us
CD BioSciences offers a wide range of professional lysosomal agonists and inhibitors. Our aim is to provide the latest agonists and inhibitors to customers around the world. Over the years, we have continuously expanded our products to meet the needs of lysosomal science research. If you are interested in our products, please contact us for product quotation and more detailed information.